Keywords: south, africa, policy, change, nevirapine, continue, providing
South Africa: no policy change on nevirapine
Article | 26 July 2004
South Africa will continue providing nevirapine (Boehringer Ingelheim'sViramune) as monotherapy to reduce the risk of mother-to-child transmission of HIV at ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Italy's pharma market slump set to continue, warns GlobalData
- Pfizer to split-off remaining 80% interest in Zoetis
